Individualized or Uniform De-Escalation Strategies for Antiplatelet Therapy in Acute Coronary Syndrome: A Review of Clinical Trials with Platelet Function Testing and Genetic Testing-Based Protocols.

Int J Mol Sci · 2023 · PMC10219318 · PMID 37240417

Europe PMC DOI

hedged sentence

0.0060

closest p · 0.1× alpha

0.0060

boldest claim

The sentences

highly significantp = 0.006actually significant

In this trial, the composite endpoint of cardiovascular death, myocardial infarction, or stroke showed a highly significant reduction favoring prasugrel vs. ticagrelor (HR: 1.36, [95% CI: 1.09–1.70], p = 0.006), and bleeding events did not differ between groups (HR: 1.12, [95% CI: 0.83–1.51], p = 0.45) [ 25 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.